This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Atherosclerosis of Aorta대동맥의 죽상경화증

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: I70.0 (atherosclerosis of aorta) | Special Copayment Reduction: V192 (special copayment reduction for heart disease: 5% copayment for up to 30 days from the registration date)
B. SynonymsAortic atherosclerosis, Aortic sclerosis, abdominal aortic atherosclerosis, Aortic plaque, aortic calcification
C. Adult onsetAtherosclerotic plaque progresses from the 40s, and clinically significant aortic atherosclerosis appears in the 60s–70s. Early onset and rapid progression are seen in men and in patients with hypertension, smoking and hyperlipidemia.
1. HistoryFoundations: von Haller's description of atheroma in 1755 and Marchand's naming of atherosclerosis (Arteriosklerose) in 1904. Milestones: the lipid hypothesis (Anitschkov, 1913) and the discovery of statins (1970s).
2. CausesHypertension, hyperlipidemia (elevated LDL-C), smoking, diabetes, obesity, advanced age, chronic kidney disease and hyperhomocysteinemia are the main risk factors.
3. GeneticsPCSK9, LDLR and APOE variants affect LDL metabolism and atherosclerosis risk. The 9p21.3 risk locus is the strongest cardiovascular risk locus identified by GWAS.
4. General epidemiologyAortic atherosclerosis is observed in 70–80% of adults aged 65 and older. Aortic plaque is a cause of aortic aneurysm, embolic stroke and peripheral arterial occlusive disease.
5. PathophysiologyEndothelial dysfunction → monocyte infiltration → foam cell formation (fatty streak) → fibrous plaque → vulnerable plaque → rupture and thrombosis. Oxidized LDL and inflammatory mediators are key.
6. SymptomsMostly asymptomatic. With progression: visceral ischemia (mesenteric ischemia), intermittent claudication of the lower limbs, and hypertension due to renal artery stenosis. Stroke and blue toes due to plaque embolism may occur.
7. SignsReduced aortic pulsation, absent lower-limb pulses, abdominal bruit, blue toes (trash foot). Aortic plaque (thickness, mobility) confirmed on transesophageal echocardiography.
8. ScreeningAbdominal ultrasound (aortic size, plaque), CT aortography, transesophageal echocardiography. The need for treatment is assessed by cardiovascular risk calculation (ASCVD Risk Score).
9. DiagnosisAbdominal and chest CT, MR angiography, transesophageal echocardiography and vascular ultrasound are used to evaluate plaque location, thickness, morphology, calcification and mobility.
10. TreatmentStatins (high intensity, adding a PCSK9 inhibitor if possible), antiplatelet agents, control of hypertension and diabetes, smoking cessation. Endovascular intervention or surgery is considered for severe aortic stenosis or embolizing plaque.
11. PrognosisAortic plaque is a strong marker of cardiovascular risk. Thick (≥4mm) or mobile plaques carry a 2–5 times higher risk of embolic stroke. Statin therapy can halt plaque progression and achieve partial regression.
12. PreventionSmoking cessation, strict control of hypertension, hyperlipidemia and diabetes, regular exercise, a Mediterranean diet and statin therapy are the cornerstones of primary prevention.
13. ReferencesAtherosclerotic plaque, cardiovascular risk, and lipid-lowering strategies: a narrative review (2025) … and 9 other papers

1. History

The history of atherosclerosis goes back thousands of years. Atherosclerotic changes have been observed in the vessels of ancient Egyptian mummies (around 1550 BC), suggesting that atherosclerosis is not solely a problem of modern lifestyles. In the 18th century, Giovanni Battista Morgagni and Albrecht von Haller began to describe pathologically the fatty lesions of the arterial intima (atheroma), and the term "atheroma" derives from the Greek "athere," meaning gruel.

In the late 19th to early 20th century, Rudolf Virchow argued that atherosclerosis is not simply fat deposition but an inflammatory response of the vascular endothelium, a pioneering insight for the modern inflammatory theory of atherosclerosis. In 1904, Felix Marchand of Germany introduced the term "Arteriosklerose (arteriosclerosis)." In 1913, Nikolai Anitschkov of Russia succeeded in artificially inducing atherosclerosis by feeding rabbits a cholesterol diet, providing the first experimental proof that cholesterol (lipid) is a key cause of atherosclerosis. This was the origin of the modern lipid hypothesis.

In the 1950s–60s, the Framingham Heart Study and the Seven Countries Study established on a large epidemiological scale that serum cholesterol, blood pressure, smoking and other factors are independent risk factors for cardiovascular disease. In the 1970s, Akira Endo, the pioneer of statins, discovered HMG-CoA reductase inhibitors, and as lovastatin, simvastatin, pravastatin and others were introduced into clinical practice in the 1980s–90s, a revolutionary change occurred in cardiovascular risk reduction. In 1994, the 4S (Scandinavian Simvastatin Survival Study) first demonstrated that simvastatin reduces cardiovascular mortality by about 30% in patients after myocardial infarction. Since the 2000s, the development of PCSK9 inhibitors has made it possible to dramatically lower LDL-C that is difficult to lower sufficiently even with statins.


2. Causes

The causes of aortic atherosclerosis are the same as those of systemic atherosclerosis, with multiple risk factors acting in combination. Dyslipidemia, particularly elevated LDL cholesterol (LDL-C), is the most direct cause of atherosclerosis. Oxidized LDL deposits in the arterial intima and becomes the key starting point of atherosclerotic plaque formation. Hypertension places mechanical stress on the vascular endothelium, causing endothelial dysfunction, which becomes the starting point of atherosclerosis. In the aorta, fluctuations in shear stress due to turbulence are particularly large at vessel branch points (origin of the celiac artery, origin of the renal arteries, bifurcation of the common iliac arteries), so atherosclerotic plaque forms more rapidly at these sites.

Smoking promotes atherosclerosis through generation of reactive oxygen species, endothelial oxidative stress, platelet activation and reduced HDL-C. Diabetes (especially type 2) accelerates vascular endothelial dysfunction and atherosclerosis through advanced glycation end products (AGEs) from hyperglycemia, oxidative stress and insulin resistance. Obesity (especially abdominal obesity) increases the risk of atherosclerosis through insulin resistance, hypertriglyceridemia, low HDL and chronic inflammation (elevated CRP, IL-6). Advanced age itself raises the risk of atherosclerosis through endothelial cell senescence, increased inflammatory responses and changes in vascular structure. Chronic kidney disease is an independent cardiovascular risk factor that promotes atherosclerosis and vascular calcification through uremic toxins, inflammation and abnormal phosphate metabolism.


3. Genetics

The contribution of genetic factors to aortic atherosclerosis is substantial. According to monozygotic twin studies, the heritability of atherosclerosis leading to cardiovascular disease is estimated at about 40 to 60%. Large-scale genome-wide association studies (GWAS) have identified more than 100 risk gene loci related to coronary artery disease and atherosclerosis.

The strongest cardiovascular risk locus is 9p21.3, located near the CDKN2A/B genes, and it increases the risk of coronary artery disease by about 25 to 40%. Variants in the LDLR (LDL receptor) gene, which is involved in LDL metabolism, cause familial hypercholesterolemia and are a major cause of premature atherosclerosis and cardiovascular disease. Gain-of-function variants in the PCSK9 gene promote degradation of the LDL receptor, raising LDL-C, whereas loss-of-function variants lower LDL-C and reduce the risk of cardiovascular disease. This discovery led to the development of PCSK9 inhibitors.

APOE gene polymorphisms (ε2, ε3, ε4) affect cholesterol metabolism, and the ε4 allele is associated with elevated LDL-C and an increased risk of atherosclerosis. The serum concentration of Lp(a) is determined mainly by the LPA gene, and a high Lp(a) level is an independent risk factor for atherosclerosis. Small nucleic acid therapeutics aimed at lowering Lp(a) (AKCEA-APO(a)-LRx, pelacarsen) are currently in clinical research.


4. General epidemiology

Aortic atherosclerosis is one of the earliest sites of manifestation of systemic atherosclerosis. According to autopsy studies, fatty streaks begin to be observed in the aorta from the early twenties, and complex atherosclerotic plaques become common in those in their fifties and older. Findings of aortic atherosclerosis are confirmed on imaging or at autopsy in about 70 to 80% of adults aged 65 and older.

According to transesophageal echocardiography (TEE) studies, an aortic atherosclerotic plaque is identified as the embolic source of stroke in about 15 to 25% of patients with cryptogenic stroke. In particular, thick complex plaques (thickness ≥4mm, mobile, ulcerated) increase the risk of stroke 2- to 5-fold. Aortic atherosclerosis is also an indicator of the severity of systemic atherosclerotic cardiovascular disease such as myocardial infarction, stroke, and peripheral arterial occlusive disease. Abdominal aortic atherosclerosis can be a precursor lesion of abdominal aortic aneurysm, and abdominal aortic aneurysm has a prevalence of about 4 to 8% in men aged 65 and older.


5. Pathophysiology

The pathophysiology of aortic atherosclerosis is a complex process of inflammation and lipid deposition that begins with endothelial dysfunction. Ross's response-to-injury hypothesis (1976) is the basis of the modern pathophysiology of atherosclerosis, and the importance of the inflammatory response has since been further emphasized.

Stage 1 (early lesion): Endothelial dysfunction caused by hypertension, turbulence, and chemical irritants (oxidized LDL, smoking) is the starting point. Decreased eNOS activity in endothelial cells reduces nitric oxide (NO) production, and increased expression of adhesion molecules such as ICAM-1 and VCAM-1 promotes monocyte infiltration into the vessel wall. The infiltrating monocytes differentiate into macrophages and phagocytose accumulated oxidized LDL to become foam cells. The accumulation of these foam cells is the fatty streak.

Stage 2 (advanced lesion): Under the influence of cytokines (TNF-α, IL-1β, IL-6) and growth factors (PDGF) secreted by macrophages and endothelial cells, smooth muscle cells in the media migrate to the intima and proliferate, secreting extracellular matrix (collagen, proteoglycans) and forming a fibrous cap. A lipid core forms beneath this fibrous cap, completing the typical atherosclerotic plaque.

Stage 3 (vulnerable plaque): A plaque in which repeated inflammation thins the fibrous cap (thin-cap fibroatheroma), the lipid core is large, neovascularization is increased, and macrophages and T cells infiltrate heavily is a "vulnerable plaque." When this plaque ruptures or erodes, platelet aggregation and thrombus formation occur, causing acute vascular events (myocardial infarction, stroke). In addition, atheroembolic disease, in which atheromatous material released from the plaque occludes downstream vessels, is an important complication.


6. Symptoms

Aortic atherosclerosis itself is characterized by progressing asymptomatically for a long time. Symptoms appear when an atherosclerotic plaque narrows a substantial portion of the aortic lumen (stenosis), involves the origins of branch vessels, becomes an embolism source, or leads to the formation of an aortic aneurysm. Because the aorta itself is a very large vessel, in most cases blood flow impairment does not occur until the internal diameter is narrowed by 70% or more.

When symptoms appear at the aortic bifurcation (Leriche syndrome: stenosis or occlusion of the abdominal aorta or iliac arteries), intermittent claudication of both lower limbs — leg pain and fatigue on walking — occurs, and erectile dysfunction may accompany it in men. Mesenteric ischemia is caused by atherosclerosis of the celiac or superior mesenteric artery, and its symptoms are postprandial abdominal pain ("intestinal angina"), weight loss, and diarrhea. Secondary hypertension and renal failure due to renal artery stenosis may also occur. Atheroembolism presents as sudden blue toe syndrome, livedo reticularis, decreased renal function, or stroke.


7. Signs

On physical examination, aortic atherosclerosis is identified by various indirect findings. An abdominal bruit is caused by stenosis of the renal arteries or abdominal aorta and is heard on auscultation over the upper or lateral abdomen. Loss of peripheral arterial pulses — diminished or absent femoral, popliteal, dorsalis pedis, and posterior tibial artery pulses — is a sign of atherosclerotic peripheral arterial occlusive disease. A pulsatile abdominal mass palpable on abdominal palpation strongly suggests an abdominal aortic aneurysm.

Signs of embolic complications of aortic atherosclerosis include acute cyanosis and mottling of the toes (blue toe syndrome), livedo reticularis, and decreased renal function. An ankle-brachial index (ABI) <0.9 suggests lower extremity arterial occlusive disease and indirectly reflects the systemic severity of aortic atherosclerosis. On transesophageal echocardiography, the thickness, mobility, and ulceration of aortic plaques are identified.


8. Screening

Screening for aortic atherosclerosis is performed as part of cardiovascular risk assessment. Blood tests include LDL-C, HDL-C, triglycerides, fasting blood glucose, HbA1c, high-sensitivity CRP (hsCRP), Lp(a), and homocysteine. The ankle-brachial index (ABI) is a noninvasive test for screening lower extremity arterial atherosclerosis, and it is recommended for patients aged 65 and older or those with diabetes or smoking.

Abdominal ultrasound is the standard method for screening for abdominal aortic aneurysm, and a single screening ultrasound is recommended for male smokers aged 65 and older. Measurement of carotid intima-media thickness (CIMT) is used to assess a surrogate marker of systemic atherosclerosis by ultrasound, but recent guidelines evaluate its role in routine screening as limited. The coronary artery calcium score (CAC score) is strongly correlated with the burden of systemic atherosclerosis and helps in deciding on preventive statin therapy in the intermediate-risk group.


9. Diagnosis

For imaging diagnosis of aortic atherosclerosis, CT angiography (CTA) is the most accurate and widely used method. CTA can rapidly evaluate the entire aorta and precisely assess the distribution of plaques, degree of calcification, luminal stenosis, and the presence of a concomitant aortic aneurysm. Calcified plaques in the aortic wall can also be identified on non-contrast CT, and the aortic calcium score quantifies the burden of aortic atherosclerosis.

Transesophageal echocardiography (TEE) is an excellent method for evaluating thoracic aortic atherosclerosis and is used as the standard for evaluating aortic embolic sources in patients with cryptogenic stroke. Plaque thickness ≥4mm, mobile components, and ulceration are features of high-risk plaques. MRI angiography (MRA) is useful for evaluating the lipid core, fibrous cap, and inflammatory activity of aortic plaques without radiation exposure. Intravascular ultrasound (IVUS) and optical coherence tomography (OCT) are used for research purposes or for evaluating plaque characteristics during procedures.


10. Treatment

Treatment of aortic atherosclerosis follows the same principles as treatment of systemic atherosclerosis, and risk factor control and drug therapy are the foundation. Statins are the key drugs in the treatment of atherosclerosis. The goal is to reduce LDL-C by 50% or more from baseline with high-intensity statins (atorvastatin 40 to 80mg, rosuvastatin 20 to 40mg) or to lower it to or below the target level (very-high-risk group: <55 mg/dL). In addition to lowering LDL-C, statins exert plaque-stabilizing, anti-inflammatory, and antithrombotic effects.

When the target is difficult to achieve with a statin alone, ezetimibe (intestinal cholesterol absorption inhibitor) or a PCSK9 inhibitor (evolocumab, alirocumab) is added. PCSK9 inhibitors can lower LDL-C by an additional 50 to 60%, making them particularly useful in patients with statin intolerance or familial hypercholesterolemia. Antiplatelet agents (aspirin, clopidogrel) are used for thrombosis prevention in patients with atherosclerotic cardiovascular disease. Hypertension treatment uses RAAS inhibitors, calcium channel blockers, and others to achieve the target blood pressure (<130/80 mmHg). When severe aortic stenosis is present, angioplasty (PTA) or surgical bypass is performed.


11. Prognosis

Aortic atherosclerosis is an indicator of the burden of systemic atherosclerosis and a strong predictor of the risk of cardiovascular events (myocardial infarction, stroke). In patients with a high-risk aortic plaque identified on TEE (thickness ≥4mm or mobile components), the risk of stroke is very high, at about 10 to 16% per year. Patients with aortic atherosclerosis have a high rate of concurrent coronary artery disease, peripheral arterial disease, and cerebrovascular disease.

Statin therapy inhibits the progression of aortic atherosclerotic plaques and induces partial regression in some cases. Studies show that after 1 year of high-intensity statin therapy, the lipid core of aortic plaques is significantly reduced, and stabilizing changes such as thickening of the fibrous cap are observed. However, complete regression of already formed calcified plaques is difficult. The prognosis of patients who develop atheroembolic disease varies with the extent of systemic organ involvement, and mortality is high when acute renal failure, stroke, and lower limb ischemia occur together.


12. Prevention

Prevention of aortic atherosclerosis is the same as prevention of systemic atherosclerosis. For primary prevention, lifelong management of cardiovascular risk factors is essential. Smoking cessation is one of the most effective single preventive measures, and cardiovascular risk decreases markedly 5 to 10 years after quitting. Regular aerobic exercise (moderate exercise for at least 150 minutes per week) contributes in combination to improving endothelial function, lowering LDL-C, raising HDL-C, and controlling blood pressure and blood glucose. A Mediterranean diet or DASH diet has been shown in a randomized controlled trial (PREDIMED) to reduce cardiovascular risk by about 25 to 30%.

Drug treatment of hyperlipidemia: for primary prevention in patients with a high 10-year cardiovascular risk, early initiation of a statin is recommended. Hypertension treatment: lowering systolic blood pressure to below 130 mmHg is effective in inhibiting the progression of atherosclerosis. Diabetes control (HbA1c target <7%) contributes to protecting vascular endothelial function. Recently, therapeutics to lower Lp(a) (RNA-based therapy, CRISPR gene editing) are being developed for patients with elevated Lp(a), so primary prevention strategies in the genetically high-risk group are expected to expand.


13. References

  1. Libby P, Buring JE, Badimon L, et al. Atherosclerosis. Nat Rev Dis Primers. 2019;5(1):56. DOI: 10.1038/s41572-019-0106-z. PMID: 31420554.

  2. Gupta A, Moli MA, Pokhrel A, et al. Atherosclerotic plaque, cardiovascular risk, and lipid-lowering strategies: a narrative review. Front Cardiovasc Med. 2025;12:1480532. DOI: 10.3389/fcvm.2025.1480532. PMID: 40012648.

  3. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2020;41(1):111-188. DOI: 10.1093/eurheartj/ehz455. PMID: 31504418.

  4. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-1722. DOI: 10.1056/NEJMoa1615664. PMID: 28304224.

  5. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383-1389. DOI: 10.1016/S0140-6736(94)90566-5. PMID: 7968073.

  6. Amarenco P, Cohen A, Tzourio C, et al. Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N Engl J Med. 1994;331(22):1474-1479. DOI: 10.1056/NEJM199412013312202. PMID: 7969297.

  7. Estruch R, Ros E, Salas-Salvadó J, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N Engl J Med. 2018;378(25):e34. DOI: 10.1056/NEJMoa1800389. PMID: 29897866.

  8. Budoff MJ, Nasir K, Mao S, et al. Relationship of coronary calcification to cardiovascular risk: an intermediate step toward validating coronary computed tomographic angiography as a screening modality. Atherosclerosis. 2013;226(2):384-390. DOI: 10.1016/j.atherosclerosis.2012.11.008. PMID: 23218822.

  9. Newman AB, Shemanski L, Manolio TA, et al. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 1999;19(3):538-545. DOI: 10.1161/01.atv.19.3.538. PMID: 10073955.

  10. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473(7347):317-325. DOI: 10.1038/nature10146. PMID: 21593864.